Gluco Track, Inc. GCTK
We take great care to ensure that the data presented and summarized in this overview for GlucoTrack, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Latest Institutional Activity in GCTK
Top Purchases
Top Sells
About GCTK
GlucoTrack, Inc., a medical device company, designs, develops, and commercializes non-invasive glucose monitoring devices for use by people suffering from diabetes and pre-diabetics in Israel and internationally. It develops GlucoTrack glucose monitoring device that helps people with diabetes and pre-diabetics to obtain blood glucose level readings without the pain. The company was formerly known as Integrity Applications, Inc. and changed its name to GlucoTrack, Inc. in November 2021. GlucoTrack, Inc. was founded in 2001 and is based in Or Yehuda, Israel.
Insider Transactions at GCTK
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Mar 26
2025
|
John Ballantyne Director |
BUY
Grant, award, or other acquisition
|
Direct |
4,126
+50.0%
|
-
|
|
Mar 26
2025
|
Luis Malave Director |
BUY
Grant, award, or other acquisition
|
Direct |
2,076
+1.42%
|
-
|
|
Mar 26
2025
|
Erin Catherine Carter Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,896
+3.99%
|
-
|
|
Mar 26
2025
|
Allen Danzig Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,498
+43.8%
|
-
|
|
Mar 26
2025
|
Andrew K Balo Director |
BUY
Grant, award, or other acquisition
|
Direct |
4,490
+50.0%
|
-
|
|
Mar 26
2025
|
Robert Fischell Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,498
+42.28%
|
-
|
|
Mar 12
2025
|
John A. Ballantyne Revocable Living Trust Dated 08/01/2017 > 10% Shareholder |
BUY
Exercise of in-the-money or at-the-money derivatives securities
|
Direct |
2,560,553
+48.27%
|
-
|
|
Mar 12
2025
|
John Ballantyne Director |
BUY
Exercise of in-the-money or at-the-money derivatives securities
|
Indirect |
2,560,553
+48.27%
|
-
|
|
Mar 12
2025
|
Luis Malave Director |
BUY
Exercise of in-the-money or at-the-money derivatives securities
|
Direct |
133,532
+48.54%
|
-
|
|
Mar 12
2025
|
Erin Catherine Carter Director |
BUY
Exercise of in-the-money or at-the-money derivatives securities
|
Direct |
40,297
+47.95%
|
-
|
|
Mar 12
2025
|
Paul Goode Chief Executive Officer |
BUY
Exercise of in-the-money or at-the-money derivatives securities
|
Direct |
15,435
+44.84%
|
-
|
|
Feb 05
2025
|
Paul Goode Chief Executive Officer |
BUY
Other acquisition or disposition
|
Direct |
1,500
+29.68%
|
-
|
|
Nov 14
2024
|
John A. Ballantyne Revocable Living Trust Dated 08/01/2017 > 10% Shareholder |
BUY
Other acquisition or disposition
|
Direct |
132,036
+41.91%
|
$4,093,116
$31.0 P/Share
|
|
Nov 14
2024
|
John Ballantyne Director |
BUY
Other acquisition or disposition
|
Indirect |
132,036
+41.91%
|
$4,093,116
$31.0 P/Share
|
|
Nov 14
2024
|
Luis Malave Director |
BUY
Conversion of derivative security
|
Direct |
6,886
+46.23%
|
$213,466
$31.2 P/Share
|
|
Nov 14
2024
|
Erin Catherine Carter Director |
BUY
Conversion of derivative security
|
Direct |
2,078
+37.67%
|
$64,418
$31.2 P/Share
|
|
Nov 14
2024
|
Paul Goode Chief Executive Officer |
BUY
Conversion of derivative security
|
Direct |
796
+27.93%
|
$24,676
$31.2 P/Share
|
|
Apr 22
2024
|
Drew Sycoff Director |
BUY
Open market or private purchase
|
Direct |
182,539
+5.82%
|
$182,539
$1.26 P/Share
|
|
Apr 08
2024
|
Luis Malave Director |
BUY
Grant, award, or other acquisition
|
Direct |
489
+30.34%
|
-
|
|
Apr 08
2024
|
Erin Catherine Carter Director |
BUY
Grant, award, or other acquisition
|
Direct |
458
+25.18%
|
-
|
Last 12 Months Summary
| Grant, award, or other acquisition | 15.6K shares |
|---|---|
| Conversion of derivative security | 9.76K shares |
| Other acquisition or disposition | 266K shares |
| Exercise of in-the-money or at-the-money derivatives securities | 5.31M shares |